Back to Journals » Research and Reports in Tropical Medicine » Volume 3

Guide to detecting a potential recrudescence of onchocerciasis during the posttreatment surveillance period: the American paradigm

Authors Cupp E, Ault, Dominguez, Eberhard, Grillet M, Morales, Nicholls, Richards F, Sauerbrey

Received 2 February 2012

Accepted for publication 2 March 2012

Published 21 May 2012 Volume 2012:3 Pages 21—33


Review by Single anonymous peer review

Peer reviewer comments 3

Program Coordinating Committee and OEPA staff

Onchocerciasis Elimination Program for the Americas, Guatemala City, Guatemala

Abstract: Control and elimination of human onchocerciasis using mass drug administration of ivermectin (Mectizan®) has proceeded with marked gains over the past 10 years, more so in the Americas than in Africa. In the Americas, the initial focus on elimination of ocular morbidity has shifted to interruption of transmission, and the program has refined both the process leading up to interruption of transmission as well as the critical period following cessation of mass drug administration to document that there is no recrudescence of transmission. This is called the posttreatment surveillance (PTS) period. This report describes the aims, phases, and methodology of PTS as operationalized by the endemic countries and the Onchocerciasis Elimination Program for the Americas. Successful completion of the PTS period without signs of recrudescence leads to a country request for certification of elimination by the World Health Organization. As elimination of onchocerciasis in the Americas proceeds and emphasis in Africa switches from control to elimination, the PTS guide should prove invaluable to those programs going forward.

Keywords: Onchocerca volvulus, onchocerciasis, ivermectin, Mectizan®, recrudescence, surveillance

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.